Newcastle University

Introduction

Please see my personal web site www.staff.ncl.ac.uk/philip.home for details of my academic and clinical activities. A full CV is available there.

Background

A full list of activities and positions is given on my personal website www.staff.ncl.ac.uk/philip.home

Roles and Responsibilities

Vice-chair, Appraisals Committee, National Institute of Clinical Excellence
Chair, Clinical Guidelines Task Force, International Diabetes Federation
President, WorldWIDE Initiative for Diabetes Education

Qualifications

BA (Oxon) 1969; DPhil (Oxon) 1974; MA (Oxon) 1974;
BM, BCh (Oxon) 1976; MRCP(UK) 1978; DM (Oxon) 1991

Previous Positions

Vice-President, International Diabetes Federation
President, European Region, International Diabetes Federation

Research Interests

International lead on many insulin and other diabetes drug developments and evaluations, new and established
International and UK lead on evidence-based diabetes guidelines

Other Expertise

Global diabetes care, structure of care delivery

Current Work

Professor of Diabetes Medicine, University of Newcastle upon Tyne
Consultant Physician, Newcastle University Hospitals NHS Trust and Newcastle Primary Care Trust
Clinical/scientific lead, NICE Type 2 diabetes guidelines, NICE Type 1 diabetes guidelines, IDF Global Guideline (also initiator and organizer)
Chairman, Clinical Guidelines Task Force, International Diabetes Federation
Vice-chair, NICE Appraisals Committee
Other Department of Health advisory groups
President WorldWDIE Inc (diabetes professional education charity)

Future Research

The RECORD study will continue to 2009. Two new long term drug evaluation studies starting 2005-6 (lead on one / steering committee on one). Two new short term insulin studies starting 2005-6 (initiator of both).

Research Roles

Total research expenditure in studies I lead runs at around £15 million per year. I spend around £100 000 to £250 000 per annum in Newcastle

Postgraduate Supervision

Currently 1 PhD (shared) and three MD students under supervision (plus one writing up). Also 1.5 research nurses, and part-funding for staff under other academics

Esteem Indicators

Global lead on clinical trials
Global and UK lead on evidence-based diabetes guidelines
Membership of many pharmaceutical global advisory boards
Invited lecturer many international diabetes meetings 2004-6
Invited lecture many national overseas (and national UK) meetings 2004-6
President of charity with funding of US0.5-1.0 million per year

Funding

My research work does not usually work that way. Expenditure of research I lead runs at around £15 million per year. In Newcastle I spend £0.1-0.25 million per year.
Guidelines income is very variable - Eur0.45 million in 2005, but more typically Eur0.05-0.1 million per year.

Industrial Relevance

Member of many global advisory boards (diabetes / cardiovascular), and lead external advisor on a number of recent new diabetes pharmaceuticals of high clinical significance.

Undergraduate Teaching

Normal University of Newcastle, Newcastle Hospitals, and Newcastle Primary Health Care student teaching

Postgraduate Teaching

PhD/MD supervision (x4); Many international and overseas/UK national lectures and teach-ins (2004-2006); Care track organiser 2006 World Diabetes Congress; President of WorldWIDE Inc (professional diabetes education charity); lead diabetes guideline developer internationally

• Home PD, Bailey CJ, Donaldson J, Chen H, Stewart MW. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with type 2 diabetes. Diabetic Medicine 2007, 24(6), 618-625.
• Al-Ozairi E, Sibal S, Home P. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): Good for Sulfonylureas?. Diabetes Care 2007, 30(6), 1677-1680.
• Dashora UK, Sibal L, Ashwell SG, Home PD. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: A randomized placebo-controlled trial. Diabetic Medicine 2007, 24(4), 344-349.
• Gallagher A, Butler TJ, Home PD. The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes. Diabetes Research and Clinical Practice 2007, 76(3), 327-334.
• Sibal L, Huong NL, Gebbie J, Home P. Cardiovascular risk factors predicting the development of distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up study. In: Adeghate, E; Saadi, H; Adem, A; Obineche, E, ed. Diabetes Mellitus and Its Complications: Molecular Mechanisms, Epidemiology, and Clinical Medicine. Hoboken, United States: Wiley-Blackwell Publishing Inc, 2006, pp.304-318.
• Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-Naïve people with type 2 diabetes. Diabetes Care 2006, 29(6), 1269-1274.
• Bagust A, Evans M, Beale S, Home PD, Perry AS, Stewart M. A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. PharmacoEconomics 2006, 24(Suppl. 1), 5-19.
• Home P. A digest of the Global Guideline for Type 2 Diabetes. Diabetes Voice 2006, 51(supplement), 1-44.
• World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva: World Health Organization, 2006.
• Home P. The diabetes epidemic and the developing world. Practical Diabetes International 2006, 23(8), 325-326.
• Home P, IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: Recommendations for standard, comprehensive, and minimal care. Diabetic Medicine 2006, 23(6), 579-593.
• Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD. Improved glycaemic control with insulin glargine plus insulin lispro: A multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabetic Medicine 2006, 23(3), 285-292.
• Hanney SR, Home PD, Frame I, Grant J, Green P, Buxton MJ. Identifying the impact of diabetes research. Diabetic Medicine 2006, 23(2), 176-184.
• Home P, Kurtzhals P. Insulin detemir: From concept to clinical experience. Expert Opinion on Pharmacotherapy 2006, 7(3), 325-343.
• Ashwell SG, Gebbie J, Home PD. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabetic Medicine 2006, 23(1), 46-52.
• Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Research and Clinical Practice 2006, 71(2), 131-139.
• Sibal L, Huong NL, Gebbie J, Dashora UK, Agarwal SC, Home P. Predicting the development of macrovascular disease in people with type 1 diabetes: A 9-year follow-up study. In: Diabetes Mellitus and Its Complications: Molecular Mechanisms, Epidemiology, and Clinical Medicine. 2006, Al Ain, United Arab Emirates: Wiley-Blackwell Publishing Inc.
• Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabetic Medicine 2006, 23(8), 879-886.
• Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A, Bartusch-Marrain P, Egger T, Francesconi M, Irsigler K, Kazerovsky-Bielesc G, Pieber T, Prager R, Weitgasser R, Saudek F, Laursen HB, Christensen C, Hermansen K, Juhl H, Soelling K, Bergkulla S, Haapamaki H, Harno K, Salmela P, Voutilainen E, Bringer J, Charbonnel B, Charpentier G, Durlach V, Gouet D, Grenier JL, Ozenne G, Penfornis A, Pinget M, Rodier M, Valensi P, Vexiau P, Warnet A, Austenat E, Beyer J, Dreyer M, Haslbeck M, Ittner JR, Landgraf R, Laube H, Lembcke HJ, Liebl A, Lotz N, Matthei S, Palitzsch KD, Paschke R, Usadel KH, Raptis S, de Heide LJM, van Hoogenhuijze J, Lutterman JA, Spooren PFMJ, Dyrbekk D, Vaaler S, Berne C, Eriksson J, Lins PE, Diem P, Gaillard R, Gray RS, Thow JC, Reckless J, Sampson M, Tindall H. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes/Metabolism Research and Reviews 2005, 21(6), 545-553.
• Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Current Medical Research and Opinion 2005, 21(7), 989-998.
• Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa J-V, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing M. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clinical Transplantation 2005, 19(3), 291-298.
• Thomas R, Home PD. Insulin therapy for people with Type 1 diabetes. Prescriber 2005, 16(6), 48-58.
• Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones NP. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol. Diabetologia 2005, 48(9), 1726-1735.
• Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes. Diabetes Research and Clinical Practice 2005, 67(3), 196-203.
• Home PD. Glucose: sweetness and toxin. Diabetes Voice, special issues: Eating 2004, 49, 5-7.
• Consoli A, Gomis R, Halimi S, Home PD, Mehnert H, Strojek K, Van Gaal LF. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: An evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes and Metabolism 2004, 30(6), 509-516.
• Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg J-E, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E. Insulin Detemir Offers Improved Glycemic Control Compared with NPH Insulin in People with Type 1 Diabetes: A randomized clinical trial. Diabetes Care 2004, 27(5), 1081-1087.
• Boehm BO, Vaz JA, Brondsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. European Journal of Internal Medicine 2004, 15(8), 496-502.
• Smith SC, Jackson R, Pearson TA, Fuster V, Yusuf S, Faergeman O, Wood DA, Alderman M, Horgan J, Home P, Hunn M, Grundy SM. Principles for national and regional guidelines on cardiovascular disease prevention - A scientific statement from the World Heart and Stroke Forum. Circulation 2004, 109(25), 3112-3121.
• Home P, Mbanya JC, Horton E. Standardisation of glycated haemoglobin [Editorial]. British Medical Journal 2004, 329(7476), 1196-1197.
• Home PD. A guide to guide diabetes guideline development. Diabetes Voice 2003, 48(3), 18-20.
• DeVries JH, Lindholm A, Jacobsen JL, Heine RJ, Home PD. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. Diabetic Medicine 2003, 20(4), 312-318.
• Home PD. Diabetes therapy and prevention of vascular damage. In: Goodfellow J.A, ed. Understanding Medical Research: The Studies That Shaped Medicine. Chichester: Wiley-Blackwell, 2012, pp.235-245.
• Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA, Home P, Kahn SE, McLellan JH, Perera R, Pluddemann A, Ramachandran A, Roberts NW, Rose PW, Schweizer A, Viberti G, Holman RR. Erratum to: Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012, 55(12), 3399-3400.
• Freemantle N, Balkau B, Danchin N, Wang E, Marre M, Vespasiani G, Kawamori R, Home PD. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes, Obesity and Metabolism 2012, 14(10), 901-909.
• Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2012.
• Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, Birkeland KI. Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes. Diabetic Medicine 2012, 29(6), 716-720.
• Home PD, Almaatouq M. Improving health outcomes in 2011 for people with type 2 diabetes: a report from a symposium held on the occasion of the International Diabetes Federation World Diabetes Congress, Dubai, 5-8 December 2011. Diabetes and Vascular Disease Research 2012, 12(2), 101-108.
• Hall GC, McMahon AD, Carroll D, Home PD. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study. Pharmacoepidemiology and Drug Safety 2012, 21(3), 305-313.
• Lepercq J, Lin J, Hall G, Dain M-P, Riddle M, Home P. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstetrics and Gynecology International 2012, 2012, 649070.
• Hall GC, McMahon AD, Carroll D, Home PD. Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease. PLoS One 2012, 7(1), e49908.
• Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes, Obesity and Metabolism 2012, 14(9), 780-788.
• Hall GC, McMahon AD, Dain MP, Home PD. A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes. Diabetes Research and Clinical Practice 2011, 94(3), 442–448.
• Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chakkarwar P, Yang W. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-western countries: The A₁chieve study. Diabetes Research and Clinical Practice 2011, 94(3), 352–363.
• Home P. Biosimilar insulins. Diabetes Voice 2011, 56(2), 40-43.
• Sibal L, Agarwal S, Home P. Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011, 4, 23-34.
• Little S, Shaw J, Home P. Hypoglycemic rates with basal insulin analogs. Diabetes Technology & Therapeutics 2011, 13(Suppl. 1), S53-S64.
• MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, McMurray JVJ. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes : a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in diabetes (RECORD) study. Diabetes Care 2011, 34(6), 1394-1396.
• Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH, Meneghini LF. Insulin Degludec in Type 1 Diabetes A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011, 34(3), 661-665.
• National Institute for Health and Clinical Excellence Quality Standards Programme. Quality standard for diabetes in adults. London: NICE, 2011. Q56.
• Home PD. Safety of PPAR agonists. Diabetes Care 2011, 34(Suppl. 2), S215-S219.
• Teoh H, Home P, Leiter LA. Should A1C targets be individualized for all people with diabetes? Arguments for and against. Diabetes Care 2011, 34(Suppl. 2), S191-S196.
• Home P. Structured care for diabetes should cover a spectrum of areas. Berkhamsted: MGP Ltd, 2011. Available at: http://www.eguidelines.co.uk/eguidelinesmain/gip/vol_14/sep_11/home_diabetes_sep11.php.
• Sibal L, Neely R, Jones A, Home P. Friedewald equation underestimates low-density lipoprotein cholesterol at low concentrations in young people with and without Type 1 diabetes. Diabetic Medicine 2010, 27(1), 37-45.
• Home PD. Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance. Evidence-Based Medicine 2010, 16(1), 10-11.
• Yang W, Zilov A, Soewondo P, Bech O, Sekkal F, Home P. Observational studies: Going beyond the boundaries of randomized controlled trials. Diabetes Research and Clinical Practice 2010, 88(1), 3-9.
• Thomas R, Home P. Recommended management of type 1 diabetes with insulin. Prescriber 2010, 21(14), 14-22.
• Fonseca V, Davidson J, Home P, Snyder J, Jellinger P, Dyhr Toft A, Barnett A. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: A pooled analysis of treat-to-target trials. Current Medical Research and Opinion 2010, 26(7), 1621-1628.
• Sibal L, Agarwal S, Home P, Boger R. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Current Cardiology Reviews 2010, 6(2), 82-90.
• Working Party of the International Diabetes Federation (European Region), Members include: PD Home (Chairman), P Senior. Hypertension in people with Type 2 diabetes: Knowledge-based diabetes-specific guidelines. Diabetic Medicine 2003, 20(12), 972-987.
• Home P, European Insulin Glargine Study Gr. A randomized, multicentre trial of insulin glargine versus NPH insulin in people with Type 1 diabetes. In: Diabetologia: 38th EASD Annual Meeting of the European Association for the Study of Diabetes. 2002, Budapest, Hungary: Springer.
• Gallagher A, Home PD. The effect of insulin aspart on post-prandial metabolism and lipid profile in Type 2 diabetes. In: Diabetologia: 38th EASD Annual Meeting of the European Association for the Study of Diabetes. 2002, Budapest, Hungary: Springer.
• Dixon S, Morrissey MI, Patel TC, Home PD, Peters JR, Bearne A, Sharplin P, Davies S, Currie CJ. The interaction between frequency of hypoglycaemia, single and multiplevascular complications and health utility. In: Diabetologia: 38th EASD Annual Meeting of the European Association for the Study of Diabetes. 2002, Budapest, Hungary: Springer.
• Boehm B, Home P, Kamp N, Lindholm A. Biphasic insulin aspart and biphasic human insulin compared in Type 2 diabetic subjects. In: 37th Annual Meeting of the EASD. 2001, Glasgow, UK: Springer.
• Amiel S, Home PD, Jacobsen JL, Lindholm A, Insulin Aspart Study Grp. Insulin aspart safe for long-term treatment. In: 37th Annual Meeting of the EASD. 2001, Glasgow, UK: Springer.
• Gallagher A, Home PD. The effect of insulin aspart on postprandial metabolism and metabolic outcome in Type 2 diabetes. In: 37th Annual Meeting of the EASD. 2001, Glasgow, UK: Springer.
• Freeman DJ, Wilson V, Canavan J, Home P, Cox VM. Changes in muscle fibre composition are associated with changes in glucose disposal in a minipig model of Type I diabetes. In: PROCEEDINGS OF THE NUTRITION SOCIETY. 2000.
• Home P, Standl E, Willms B. Guide for type 1 diabetes mellitus. Diabetes und Stoffwechsel 2000, 9(3), 173-204.
• Gallagher A, Home PD. The effect of insulin aspart on metabolic outcomes and albumin excretion in Type 2 diabetes. In: DIABETOLOGIA. 2000.
• Home P. Insulin glargine: The first clinically useful extended-acting insulin in half a century?. Expert Opinion on Investigational Drugs 1999, 8(3), 307-314.
• Home P. Rapid-acting insulin secretagogues: a clinical need?. In: Satellite Symposium on Repaglinide: A New Dimension in the Management of Type 2 Diabetes. 1999, Barcelona, Spain: J. A. Barth Verlag.
• Home P. Untitled - Foreword. Diabetes, Obesity and Metabolism 1999, 1, SV-SV.